VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

Cancer Cell

Volumn 4, Issue 4, 2003, Pages 263-275

  Stojdl, David F ^a   Lichty, Brian D ^a   TenOever, Benjamin R ^b   Paterson, Jennifer M ^a,f   Power, Anthony T ^a,f   Knowles, Shane ^a   Marius, Ricardo ^a   Reynard, Jennifer ^a   Poliquin, Laurent ^c   Atkins, Harold ^a   Brown, Earl G ^f   Durbin, Russell K ^d   Durbin, Joan E ^d   Hiscott, John ^b,e   Bell, John C ^a,f  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^d OHIO STATE UNIVERSITY   (United States)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ONCOLYTIC VIRUS; RECOMBINANT INTERFERON; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS M PROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL KILLING; CELLULAR IMMUNITY; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; FEMALE; HUMAN; HUMAN CELL; INFECTION PREVENTION; METASTASIS; MICROBIAL ACTIVITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL; UNINDEXED SEQUENCE; VESICULAR STOMATITIS VIRUS; VIRUS CELL INTERACTION; VIRUS MUTANT; VIRUS REPLICATION; XENOGRAFT;

ANIMALIA; VESICULAR STOMATITIS VIRUS;

EID: 10744223476     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00241-1     Document Type: Article

References (52)

1. Ahmed M., McKenzie M.O., Puckett S., Hojnacki M., Poliquin L., Lyles D.S. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J. Virol. 77:2003;4646-4657.
2. Balachandran S., Barber G.N. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life. 50:2000;135-138.
3. Balachandran S., Roberts P.C., Brown L.E., Truong H., Pattnaik A.K., Archer D.R., Barber G.N. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity. 13:2000;129-141.
4. Barchet W., Cella M., Odermatt B., Asselin-Paturel C., Colonna M., Kalinke U. Virus-induced interferon alpha production by a dendritic cell subset in the absence of feedback signaling in vivo. J. Exp. Med. 195:2002;507-516.
5. Bell J.C., Garson K.A., Lichty B.D., Stojdl D.F. Oncolytic viruses. programmable tumour hunters Curr. Gene Ther. 2:2002;243-254.
6. Bello M.J., de Campos J.M., Kusak M.E., Vaquero J., Sarasa J.L., Pestana A., Rey J.A. Molecular analysis of genomic abnormalities in human gliomas. Cancer Genet. Cytogenet. 73:1994;122-129.
7. Blondel D., Harmison G.G., Schubert M. Role of matrix protein in cytopathogenesis of vesicular stomatitis virus. J. Virol. 64:1990;1716-1725.
8. Coulon P., Deutsch V., Lafay F., Martinet-Edelist C., Wyers F., Herman R.C., Flamand A. Genetic evidence for multiple functions of the matrix protein of vesicular stomatitis virus. J. Gen. Virol. 71:1990;991-996.
9. Desforges M., Charron J., Berard S., Beausoleil S., Stojdl D.F., Despars G., Laverdiere B., Bell J.C., Talbot P.J., Stanners C.P., Poliquin L. Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells. Virus Res. 76:2001;87-102.
10. DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature. 388:1997;548-554.
11. Ferran M.C., Lucas-Lenard J.M. The vesicular stomatitis virus matrix protein inhibits transcription from the human beta interferon promoter. J. Virol. 71:1997;371-377.
12. Francoeur A.M., Poliquin L., Stanners C.P. The isolation of interferon-inducing mutants of vesicular stomatitis virus with altered viral P function for the inhibition of total protein synthesis. Virology. 160:1987;236-245.
13. Genin P., Algarte M., Roof P., Lin R., Hiscott J. Regulation of RANTES chemokine gene expression requires cooperativity between NF-kappa B and IFN-regulatory factor transcription factors. J. Immunol. 164:2000;5352-5361.
14. Gromeier M., Wimmer E. Viruses for the treatment of malignant glioma. Curr. Opin. Mol. Ther. 3:2001;503-508.
15. Hawkins L.K., Lemoine N.R., Kirn D. Oncolytic biotherapy. a novel therapeutic plafform Lancet Oncol. 3:2002;17-26.
16. Her L.S., Lund E., Dahlberg J.E. Inhibition of Ran guanosine triphosphatase-dependent nuclear transport by the matrix protein of vesicular stomatitis virus. Science. 276:1997;1845-1848.
17. Hieronymus H., Silver P.A. Genome-wide analysis of RNA-protein interactions illustrates specificity of the mRNA export machinery. Nat. Genet. 33:2003;155-161.
18. Huneycutt B.S., Bi Z., Aoki C.J., Reiss C.S. Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J. Virol. 67:1993;6698-6706.
19. Ikeda K., Wakimoto H., Ichikawa T., Jhung S., Hochberg F.H., Louis D.N., Chiocca E.A. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. 74:2000;4765-4775.
20. Jayakar H.R., Murti K.G., Whitt M.A. Mutations in the PPPY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release. J. Virol. 74:2000;9818-9827.
21. Kashtan H., Rabau M., Mullen J.B., Wong A.H., Roder J.C., Shpitz B., Stern H.S., Gallinger S. Intra-rectal injection of tumour cells. a novel animal model of rectal cancer Surg. Oncol. 1:1992;251-256.
22. Kruyt F.A., Curiel D.T. Toward a new generation of conditionally replicating adenoviruses. pairing tumor selectivity with maximal oncolysis Hum. Gene Ther. 13:2002;485-495.
23. Lawson N.D., Stillman E.A., Whitt M.A., Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. USA. 92:1995;4477-4481.
24. Levy D.E. Whence interferon? Variety in the production of interferon in response to viral infection. J. Exp. Med. 195:2002;F15-F18.
25. Lin R., Mamane Y., Hiscott J. Multiple regulatory domains control IRF-7 activity in response to virus infection. J. Biol. Chem. 275:2000;34320-34327.
26. Linge C., Gewert D., Rossmann C., Bishop J.A., Crowe J.S. Interferon system defects in human malignant melanoma. Cancer Res. 55:1995;4099-4104.
27. Lu R., Au W.C., Yeow W.S., Hageman N., Pitha P.M. Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon and silencing by hypermethylation. J. Biol. Chem. 275:2000;31805-31812.
28. Lyles D.S., McKenzie M.O., Ahmed M., Woolwine S.C. Potency of wild-type and temperature-sensitive vesicular stomatitis virus matrix protein in the inhibition of host-directed gene expression. Virology. 225:1996;172-180.
29. Matin S.F., Rackley R.R., Sadhukhan P.C., Kim M.S., Novick A.C., Bandyopadhyay S.K. Impaired alpha-interferon signaling in transitional cell carcinoma. lack of p48 expression in 5637 cells Cancer Res. 61:2001;2261-2266.
30. Morin P., Braganca J., Bandu M.T., Lin R., Hiscott J., Doly J., Civas A. Preferential binding sites for interferon regulatory factors 3 and 7 involved in interferon-A gene transcription. J. Mol. Biol. 316:2002;1009-1022.
31. Nakaya T., Sato M., Hata N., Asagiri M., Suemori H., Noguchi S., Tanaka N., Taniguchi T. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem. Biophys. Res. Commun. 283:2001;1150-1156.
32. Newcomb W.W., Tobin G.J., McGowan J.J., Brown J.C. In vitro reassembly of vesicular stomatitis virus skeletons. J. Virol. 41:1982;1055-1062.
33. Norman K.L., Farassati F., Lee P.W. Oncolytic viruses and cancer therapy. Cytokine Growth Factor Rev. 12:2001;271-282.
34. Novella I.S., Cilnis M., Elena S.F., Kohn J., Moya A., Domingo E., Holland J.J. Large-population passages of vesicular stomatitis virus in interferon-treated cells select variants of only limited resistance. J. Virol. 70:1996;6414-6417.
35. Petersen J.M., Her L.S., Varvel V., Lund E., Dahlberg J.E. The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol. Cell. Biol. 20:2000;8590-8601.
36. Sato M., Hata N., Asagiri M., Nakaya T., Taniguchi T., Tanaka N. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 441:1998;106-110. a.
37. Sato M., Tanaka N., Hata N., Oda E., Taniguchi T. Involvement of the IRF family transcription factor IRF-3 in virus-induced activation of the IFN-beta gene. FEBS Lett. 425:1998;112-116. b.
38. Sharma S., tenOever B.R., Grandvaux N., Zhou G.P., Lin R., Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science. 300:2003;1148-1151.
39. Specht J.M., Wang G., Do M.T., Lam J.S., Royal R.E., Reeves M.E., Rosenberg S.A., Hwu P. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186:1997;1213-1221.
40. Steinhoff U., Muller U., Schertler A., Hengartner H., Aguet M., Zinkernagel R.M. Antiviral protection by vesicular stomatitis virus-specific antibodies in alpha/beta interferon receptor-deficient mice. J. Virol. 69:1995;2153-2158.
41. Stojdl D.F., Abraham N., Knowles S., Marius R., Brasey A., Lichty B.D., Brown E.G., Sonenberg N., Bell J.C. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J. Virol. 74:2000;9580-9585. a.
42. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., Bell J.C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:2000;821-825. b.
43. Sun W.H., Pabon C., Alsayed Y., Huang P.P., Jandeska S., Uddin S., Platanias L.C., Rosen S.T. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood. 91:1998;570-576.
44. Terstegen L., Gatsios P., Ludwig S., Pleschka S., Jahnen-Dechent W., Heinrich P.C., Graeve L. The vesicular stomatitis virus matrix protein inhibits glycoprotein 130-dependent STAT activation. J. Immunol. 167:2001;5209-5216.
45. von Kobbe C., van Deursen J.M., Rodrigues J.P., Sitterlin D., Bachi A., Wu X., Wilm M., Carmo-Fonseca M., Izaurralde E. Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol. Cell. 6:2000;1243-1252.
46. Wakimoto H., Ikeda K., Abe T., Ichikawa T., Hochberg F.H., Ezekowitz R.A., Pasternack M.S., Chiocca E.A. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. 5:2002;275-282.
47. Wakimoto H., Johnson P.R., Knipe D.M., Chiocca E.A. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. 10:2003;983-990.
48. Wathelet M.G., Lin C.H., Parekh B.S., Ronco L.V., Howley P.M., Maniatis T. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol. Cell. 1:1998;507-518.
49. Wein L.M., Wu J.T., Kirn D.H. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment. implications for virus design and delivery Cancer Res. 63:2003;1317-1324.
50. Wong L.H., Krauer K.G., Hatzinisiriou I., Estcourt M.J., Hersey P., Tam N.D., Edmondson S., Devenish R.J., Ralph S.J. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J. Biol. Chem. 272:1997;28779-28785.
51. Yoon S.K., Armentano D., Wands J.R., Mohr L. Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice. Cancer Gene Ther. 8:2001;573-579.
52. Yuan H., Puckett S., Lyles D.S. Inhibition of host transcription by vesicular stomatitis virus involves a novel mechanism that is independent of phosphorylation of TATA-binding protein (TBP) or association of TBP with TBP-associated factor subunits. J. Virol. 75:2001;4453-4458.